Budapest, Hungary – Basel, Switzerland / Cambridge, Mass., USA – 2 November 2023 – Gedeon Richter Plc. (‘Richter’) together with Sumitomo Pharma America, Inc. (‘SMPA’) and Sumitomo Pharma Switzerland, GmbH […]

Budapest, Hungary – Basel, Switzerland / Cambridge, Mass., USA – 15 September 2023 – Gedeon Richter Plc. (‘Richter’) together with Sumitomo Pharma America, Inc. (‘SMPA’) and Sumitomo Pharma Switzerland (‘SMPS’) […]

Gedeon Richter Plc. today announced that it has submitted a Type II Variation application for Ryeqo® (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) to the European […]

Budapest, Hungary – 20 July 2021 – Gedeon Richter Plc. (‘Richter’) announces that the European Commission (‘EC’) has granted approval for the marketing authorisation of Ryeqo® a novel oral treatment […]

Budapest, Hungary and Basel, Switzerland – Myovant Sciences (NYSE:MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, and Gedeon Richter Plc., a major pharmaceutical company […]